Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050 DOI Creative Commons
Phuc Le, Moosa Tatar, Srinivasan Dasarathy

et al.

JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(1), P. e2454707 - e2454707

Published: Jan. 17, 2025

Importance Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common cause of chronic and projected to become leading indication for transplant (LT) in US. Understanding its clinical burden can help identify opportunities prevention treatment. Objective To project MASLD US adults from 2020 2050. Design, Setting, Participants This decision analytical modeling study used an agent-based state transition model that simulates natural history progression among 18 years age or older. Primary data sources inputs were published literature. Exposure Natural MASLD. Main Outcomes Measures Cases MASLD, metabolic steatohepatitis (MASH), fibrosis, hepatocellular carcinoma (HCC), LT, liver-related death. Results The simulated 2 821 624 individuals (mean age. 35.8 years; 50.9% female). predicted a steady increase prevalence 33.7% (86.3 million people) 41.4% (121.9 by MASH would 14.9 (5.8% adults) 23.2 (7.9% number cases clinically significant fibrosis (ie, F≥F2, centrilobular periportal more severe disease) estimated 6.7 11.7 million. By 2046 2050, 22 440 new HCC 6720 LT per year compared with 11 483 1717 2025. Liver-related mortality was 30 500 deaths (1.0% all-cause 95 300 (2.4%) Conclusions Relevance In this study, forecast substantial over next 3 decades absence effective treatments. These results suggest health systems should plan large increases need LT.

Language: Английский

Current status and future perspectives of FGF21 analogues in clinical trials DOI
Zara Siu Wa Chui, Qing Shen, Aimin Xu

et al.

Trends in Endocrinology and Metabolism, Journal Year: 2024, Volume and Issue: 35(5), P. 371 - 384

Published: Feb. 28, 2024

Language: Английский

Citations

18
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease DOI Creative Commons
Xiaolong Qi, Jie Li, Cyrielle Caussy

et al.

Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: May 8, 2024

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as NAFLD, is increasingly recognized a prevalent global burden. Type 2 diabetes mellitus (T2DM), another important metabolic disease, considered major contributor to the development of MASLD. MASLD and T2DM have strong association with each other due shared pathogenic mechanisms. The co-existence diseases increases risk liver-related adverse outcomes imposes heavier burden on extrahepatic outcomes, representing substantial public health issue. Effective assessment management combined necessitate multidisciplinary approach. emergence numerous RCTs has shed light treatment This review uncovers epidemiology intertwined MASLD, offers insights into evaluation hepatic fibrosis in patients T2DM, glucose monitoring population, provides comprehensive co-management strategies for addressing both diseases.

Language: Английский

Citations

18
Pathological mechanisms of kidney disease in ageing DOI
Takeshi Yamamoto, Yoshitaka Isaka

Nature Reviews Nephrology, Journal Year: 2024, Volume and Issue: 20(9), P. 603 - 615

Published: July 18, 2024

Language: Английский

Citations

18
MASH clinical trials and drugs pipeline: An impending tsunami DOI
Mazen Noureddin

Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: March 19, 2024

Metabolic dysfunction–associated steatotic liver disease, formerly known as NAFLD, has ascended to prominence the predominant chronic disease in Western countries and now stands a leading cause of transplantations. In more advanced stage, metabolic steatohepatitis (MASH) may lead fibrosis, gateway cirrhosis, cancer, failure. Despite extensive research exploration various drug mechanisms, anticipation for inaugural approved materialize by 2024 is palpable, marking significant milestone. Numerous pathways have been investigated MASH treatment, exploring thyroid hormone receptors, glucagon-like peptides 1, peroxisome proliferator–activated agents influencing hepatic steatosis synthesis, inflammatory pathways, genetic components, fibrosis an array other avenues. Over time, key regulatory directions crystallized, manifesting 2 primary endpoints under investigation: resolution without worsening and/or improvement stage steatohepatitis, especially used phase 3 clinical trials, while alternative noninvasive are explored trials. The prospect proving efficacy trials opens doors combination therapies, evaluating ideal drugs yield comprehensive benefits, extending beyond organs. Certain already underway. this review, we discuss forefront 2023/2024, illuminating outcomes, future trajectories. Furthermore, tackle challenges confronting propose potential strategies surmounting them.

Language: Английский

Citations

17
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050 DOI Creative Commons
Phuc Le, Moosa Tatar, Srinivasan Dasarathy

et al.

JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(1), P. e2454707 - e2454707

Published: Jan. 17, 2025

Importance Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common cause of chronic and projected to become leading indication for transplant (LT) in US. Understanding its clinical burden can help identify opportunities prevention treatment. Objective To project MASLD US adults from 2020 2050. Design, Setting, Participants This decision analytical modeling study used an agent-based state transition model that simulates natural history progression among 18 years age or older. Primary data sources inputs were published literature. Exposure Natural MASLD. Main Outcomes Measures Cases MASLD, metabolic steatohepatitis (MASH), fibrosis, hepatocellular carcinoma (HCC), LT, liver-related death. Results The simulated 2 821 624 individuals (mean age. 35.8 years; 50.9% female). predicted a steady increase prevalence 33.7% (86.3 million people) 41.4% (121.9 by MASH would 14.9 (5.8% adults) 23.2 (7.9% number cases clinically significant fibrosis (ie, F≥F2, centrilobular periportal more severe disease) estimated 6.7 11.7 million. By 2046 2050, 22 440 new HCC 6720 LT per year compared with 11 483 1717 2025. Liver-related mortality was 30 500 deaths (1.0% all-cause 95 300 (2.4%) Conclusions Relevance In this study, forecast substantial over next 3 decades absence effective treatments. These results suggest health systems should plan large increases need LT.

Language: Английский

Citations

8